NLS Pharmaceutics (NASDAQ: NLSPW) pushes Kadimastem merger deadline to Oct 31, 2025

Rhea-AI Filing Summary

NLS Pharmaceutics Ltd. filed a Form 6-K to report that it entered into a seventh amendment to its Agreement and Plan of Merger with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. The amendment extends the merger agreement’s termination date from August 31, 2025 to October 31, 2025 to allow more time to complete the merger.

The extension is intended to provide additional time for NLS Pharmaceutics to receive and evaluate further comments from the U.S. Securities and Exchange Commission on its pending Form F-4 registration statement for the proposed merger transaction with Kadimastem. The parties state that they remain focused on and committed to completing the merger and are working to satisfy all regulatory and closing requirements.

Insights

Cross-border M&A and regulatory process analyst

NLS Pharmaceutics and Kadimastem extend their merger deadline to allow more SEC review time.

The key development is a seventh amendment to the merger agreement between NLS Pharmaceutics, Kadimastem, and NLS Pharmaceutics (Israel) Ltd., moving the termination date from August 31, 2025 to October 31, 2025. This reflects that the combination is still pending rather than complete and that the parties are adjusting their contractual timetable to current regulatory progress.

The filing links the extension directly to ongoing SEC review of the Form F-4 registration statement, noting the need to receive and evaluate further SEC comments. This indicates that the transaction remains in the regulatory clearance phase and that timing depends on completion of that review and satisfaction of closing conditions, including shareholder approvals referenced in the risk discussion.

The parties reiterate that they remain fully committed to completing the merger and are working to meet all regulatory requirements. Actual completion will depend on resolving SEC comments, fulfilling closing conditions, and obtaining required shareholder approvals, so subsequent disclosures about the F-4 and voting process will be important for understanding if and when the merger closes.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of August 2025 (Report No. 3)

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

CONTENTS

Seventh Amendment to the Merger Agreement

On August 29, 2025, NLS Pharmaceutics Ltd. (the “Company”) entered into a seventh amendment (the “Seventh Amendment”) to the Agreement and Plan of Merger, dated November 4, 2024, and as previously amended on January 30, 2025, February 17, 2025, May 5, 2025, June 5, 2025, July 1, 2025, and on July 18, 2025 (the “Merger Agreement”) among the Company, Kadimastem Ltd. (“Kadimastem”) and NLS Pharmaceutics (Israel) Ltd. (collectively, the “Parties”).

Pursuant to the Seventh Amendment, the Parties agreed to extend the Merger Agreement’s termination date from August 31, 2025 to October 31, 2025 in order to complete the merger.

This extension is intended to allow additional time for the Company to receive and evaluate further comments from the U.S. Securities and Exchange Commission on the Company’s pending registration statement on Form F-4 relating to the proposed merger transaction with Kadimastem. The Parties remain focused on and fully committed to aligning their efforts to completing the merger as soon as possible and with the utmost diligence. The Parties are actively working to fulfill all commitments related to the process and adhere to the requirements set forth by all regulatory agents.

Safe Harbor Statement

This Report of Foreign Private Issuer on Form 6-K contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company and Kadimastem are using forward-looking statements when they discuss the expected completion of the transaction. These forward-looking statements and their implications are based on the current expectations of the management of the Company and Kadimastem and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks related to the companies’ ability to complete the merger on the proposed terms and schedule, including risks and uncertainties related to the satisfaction of the closing conditions related to the merger agreement and risks and uncertainties related to the failure to timely, or at all, obtain shareholder approvals for the transaction; and unexpected costs, charges or expenses resulting from the transaction and potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed merger. Except as otherwise required by law, neither Kadimastem nor the Company undertakes any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”), which is available on the SEC’s website, www.sec.gov, and in subsequent filings made by the Company with the SEC.

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

1

Additional Information about the Transaction and Where to Find It

In connection with the proposed transaction, the Company filed a registration statement on Form F-4 on December 30, 2024, including a proxy statement/prospectus, with the SEC (the “F-4 Registration Statement”), and subsequent Amendments to the F-4 Registration Statement on March 3, 2025, March 31, 2025, June 9, 2025, June 23, 2025, July 18, 2025, and July 29, 2025. The Company may also file other relevant documents regarding the proposed transaction with the SEC, including an amendment to the F-4 Registration Statement. This document is not a substitute for the proxy statement/prospectus or any other document that the Company may file with the SEC. The proxy statement (if and when available) will be mailed to shareholders of the Company. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of the proxy statement/prospectus (if and when available) and other documents containing important information about the Company and the proposed transaction, once such documents are filed with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on the Company’s website at www.nlspharma.com.

Participants in the Solicitation

The Company and certain of its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company’s shareholders in respect of the proposed transaction. Information about the directors and executive officers of the Company, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, which was filed with the SEC on May 16, 2025. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the F-4 Registration Statement and other relevant materials to be filed with the SEC regarding the proposed transaction when such materials become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the Company using the sources indicated above.

EXHIBIT INDEX

Exhibit Number		Description of Document
99.1		Seventh Amendment to the Agreement and Plan of Merger, dated August 29, 2025, among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel Ltd.), and Kadimastem Ltd.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NLS Pharmaceutics Ltd.
Date: August 29, 2025	By:	/s/ Alexander Zwyer
		Name:	Alexander Zwyer
		Title:	Chief Executive Officer

3

FAQ

What did NLS Pharmaceutics Ltd. (NLSPW) announce in this Form 6-K?

NLS Pharmaceutics Ltd. reported that it entered into a seventh amendment to its Agreement and Plan of Merger with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. The amendment extends the merger agreement’s termination date to October 31, 2025 to provide more time to complete the proposed merger.

Why was the NLS Pharmaceutics and Kadimastem merger deadline extended to October 31, 2025?

The termination date was extended to October 31, 2025 to allow additional time for NLS Pharmaceutics to receive and evaluate further comments from the U.S. Securities and Exchange Commission on its pending Form F-4 registration statement related to the proposed merger with Kadimastem.

Is the NLS Pharmaceutics (NLSPW) merger with Kadimastem still active?

Yes. By signing the seventh amendment and extending the termination date, the parties state they remain focused on and fully committed to aligning their efforts to complete the merger and are actively working to fulfill all commitments and regulatory requirements.

What regulatory filing is tied to the NLS Pharmaceutics–Kadimastem merger?

The proposed merger is tied to a registration statement on Form F-4, which includes a proxy statement/prospectus. The company filed the original Form F-4 on December 30, 2024 and has submitted multiple amendments as SEC review continues.

Where can NLS Pharmaceutics (NLSPW) investors find the Form F-4 and proxy materials for the merger?

Investors will be able to obtain free copies of the Form F-4, the proxy statement/prospectus (if and when available), and related documents through the SEC’s website at http://www.sec.gov and via NLS Pharmaceutics’ website at www.nlspharma.com.

Does this NLS Pharmaceutics 6-K constitute an offer to buy or sell securities?

No. The communication states that it does not constitute an offer to buy or sell any securities or a solicitation of any vote or approval. Any offering of securities would be made only by means of a prospectus meeting the requirements of Section 10 of the Securities Act.